CRL Stock News 53.83 05/14/2014 19:57:11 Charles River Laboratories

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Charles River Laboratories Intl (CRL) 53.83 $CRL

Charles River Laboratories Earnings In Retrospect: Down 0.6% in the Last 12 Days (CRL)
Comtex SmarTrend(R) - Mon May 12, 8:45AM CDT
A week ago on April 30th, 2014 Charles River Laboratories (NYSE:CRL) reported earnings and analysts, on average, expected earnings of $0.74 on sales of $302.2 million. Charles River Laboratories actually reported earnings of $0.82 per share on sales of $299.4 million, beating EPS estimates by $0.08 and missing revenue estimates by $2.8 million. Shares of Charles River Laboratories have slipped from $53.72 to $53.39, representing a loss of 0.6%, since the company reported earnings 12 days ago.

Earnings Results, Esteemed Recognitions, and Conference Call Schedules - Analyst Notes on Covance, Alere, LabCorp, Charles River and WuXi PharmaTech
PR Newswire - Thu May 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Covance Inc. (NYSE: CVD), Alere Inc. (NYSE: ALR), Laboratory Corp. of America Holdings (NYSE: LH), Charles River Laboratories International, Inc. (NYSE: CRL) and WuXi PharmaTech (Cayman) Inc. (NYSE: WX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2179-100free.

Charles River Laboratories to Present at Baird's Growth Stock Conference
Business Wire - Mon May 05, 4:00PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at Baird's 2014 Growth Stock Conference in Chicago, Illinois on Wednesday, May 7th, at 10:20 a.m. CDT (11:20 a.m. EDT). Management will present an overview of Charles River's strategic focus and business developments.

Shares of CRL Down 11.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon May 05, 9:21AM CDT
SmarTrend identified a Downtrend for Charles River Laboratories (NYSE:CRL) on April 7th, 2014 at $56.82. In approximately 4 weeks, Charles River Laboratories has returned 11.85% as of today's recent price of $50.08.

Charles River Laboratories (CRL) is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 8:50AM CDT
Charles River Laboratories (CRL) is now in Oversold Territory

Life Sciences BPO Market Report with Forecasts to 2019: Contract Research Organizations & Contract Manufacturing Organizations
M2 - Fri May 02, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zvdqxl/life_sciences_bpo) has announced the addition of the "Life Sciences BPO Market Report with Forecasts to 2019: Contract Research Organizations & Contract Manufacturing Organizations" report to their offering. The major players of this market are CatalentPharma Solutions, PRA International, Covance, Quintiles, Parexel, DSM, Charles River Laboratories, Piramal Healthcare and BoehringerIngelheim. Economic burden, increased financial crisis and technological advances has compelled all pharmaceutical, biotechnology and life science companies to outsource their R&D activities and manufacturing processes in order to achieve their cost benefits and save time.In recent years, large number of life science companies has modified their traditional drug manufacturing operations with more focus now on their core R&D activities and manufacturing processes via outsourcing. Global Life Sciences BPO market includes Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs) and others that compriseContract Sales Organization (CSO). The contract manufacturing organizations market is expected to see the highest growth rate during the forecast period and also accounted for the largest market share in the year 2012. This market holds immense growth owing to the rise in demand for generic drugs, increase in R&D investment by life sciences companies. In addition, a rise in the number of block buster drugs going off-patent and increased adoption of novel technologies are further boosting the growth of this market. The CMO market comprises contract API (Active Pharmaceutical Ingredients) manufacturing, contract FDF (Finished Dosage Formulations) manufacturing and packaging.Among these, contract FDF manufacturing segment is expected to have a healthy growth rate during the forecast period. The CRO market is also expected to display a healthy growth rate after CMO market. The CRO market comprises of various segments such as drug discovery, pre-clinical studies, clinical trial phases, medical writing, clinical data management, pharmacovigilance, regulatory services, site management, protocol development, monitoring and bio-statistics. Among these, clinical data management segment is expected to have a strong growth rate in coming years. This growth has been attributed to its high data complexities, high cost involvement and requirement of skilled & trained professionals. Scope Contract Research Organizations - Drug Discovery - Pre-Clinical - Clinical Trials - Medical Writing - Pharmacovigilance - Risk-Based Monitoring - Clinical Data Management - Biostatistics Contract Manufacturing Organizations Companies Mentioned - Accenture, Plc - Boehringer Ingelheim GmbH - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. (CRL) - Cognizant Technology Solutions - Covance, Inc. - DSM - Fareva - ICON, Plc - Infosys - International Business Machines Corporation - Lonza Group - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Parexel International Corporation - Patheon, Inc. - Piramal Healthcare - PRA International, Inc. - Quintiles Transnational Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/zv...iences_bpo

Charles River Beats on Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 2:34PM CDT
Charles River Laboratories (CRL) reported first quarter 2014 earnings (excluding special items) of 82 cents per share, easily beating the Zacks Consensus Estimate of 74 cents and up from 69 cents in the year-ago quarter.

Charles River Laboratories Announces First-Quarter 2014 Results from Continuing Operations
Business Wire - Wed Apr 30, 3:31PM CDT
--- First-Quarter GAAP Earnings per Share of $0.67 and Non-GAAP Earnings per Share of $0.82 -

Express Scripts Misses Earnings, Guides Low - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 10:50AM CDT
Express Scripts Holding Company (ESRX) posted first quarter 2014 earnings per share (excluding special items) of 99 cents, flat with the year-ago quarter. However, the result fell short of the Zacks Consensus Estimate of $1.01

Is Charles River Laboratories (CRL) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 7:49AM CDT
Charles River Labs is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

IPC The Hospitalist (IPCM) in Focus: Stock Slumps 12.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 7:43AM CDT
IPC The Hospitalist falls 12.2% last trading session, continuing the downtrend

Research and Markets: Global In-vitro Toxicity Testing Market 2014-2018 with Accelrys, Bio-Rad Laboratories, Charles River Laboratories International & Covance Dominating
Business Wire - Wed Apr 23, 12:00PM CDT
Research and Markets (http://www.researchandmarkets.com/research/t58qhp/global_invitro) has announced the addition of the "Global In-vitro Toxicity Testing Market 2014-2018" report to their offering.

Global In-vitro Toxicity Testing Market 2014-2018 with Accelrys, Bio-Rad Laboratories, Charles River Laboratories International & Covance Dominating
M2 - Wed Apr 23, 9:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7txnm/global_invitro) has announced the addition of the "Global In-vitro Toxicity Testing Market 2014-2018" report to their offering. The analysts forecast the Global In Vitro Toxicity Testing market will grow at a CAGR of 15.84 percent over the period 2013-2018. The Global In Vitro Toxicity Testing market is driven by several factors, of which an increase in opposition to animal testing is one of the major drivers. Since animals are used as test subjects, toxicity testing is opposed by the majority of animal rights activists. This results in the increased adoption of in vitro toxicity testing and helps in the growth of the market. Animal welfare organizations across the world are supporting in vitro toxicity testing. Cosmetic as well as chemical companies are trying to market and sell their products by campaigning animal-free testing. Popular brands of cosmetics are implementing animal-free testing policies to market and sell their products. Vendors are targeting compassionate consumers by marketing their products as cruelty-free food, cosmetics, and clothing as cruelty-free testing does not damage the environment or produce harmful waste. For instance, the Body Shop follows a no-animal-tests policy to sell its products. Thus, the increase in animal-free testing campaigns has opened up new avenues for the market. Further, the report states that the accuracy and reliability of in vitro toxicity testing is one of the major challenges faced by the market vendors. In vitro toxicity testing requires proper laboratory setup as well as high-quality cell and tissue culture and good aseptic techniques. The Global In Vitro Toxicity Testing market can be divided into four end-user segments: - Cosmetics and Personal Care Industry - Pharmaceuticals Industry - Food Industry - Chemicals Industry. Key Vendors - Accelrys Inc. - Bio-Rad Laboratories Inc. - Charles River Laboratories International Inc. - Covance Inc. Other Prominent Vendors - Entelos Inc. - Mattek Corp. - Molecular Toxicology Inc. - RTI Health Solutions - SBW Ltd. - Smithers Group Inc. - Xenobiotic Detection Systems Inc. - Xenometrix AG Key Market Drivers/Challenges/Trends - Increasing Opposition to Animal Testing. - Concerns about Accuracy and Reliability of the Test. - Increase in Animal-free Testing Campaigns. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Toxicology - Market Landscape - Market Segmentation by End-users - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/p7...al_invitro

Technical Coverage on Health Care Equities -- Research on MEDNAX, Covance, PAREXEL Intl., and Charles River Laboratories Intl.
PR Newswire - Tue Apr 22, 11:55AM CDT
On Monday, April 21, 2014, the NASDAQ Composite ended at 4,121.55, up 0.64%, the Dow Jones Industrial Average advanced 0.25% to 16,449.25, and the S&P 500 closed at 1,871.89, up 0.38%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 666.48, up 1.20%, while the same has declined 3.26% in the last one month. Investor-Edge has initiated coverage on the following equities: MEDNAX Inc. (NYSE: MD), Covance Inc. (NYSE: CVD), PAREXEL International Corp. (NASDAQ: PRXL) and Charles River Laboratories International Inc. (NYSE: CRL). Free technical research on MD, CVD, PRXL and CRL can be downloaded upon signing up at:

In Vitro Toxicity Testing to Grow at a 15.84% CAGR to 2018 Says a New Research Report at ReportsnReports.com
PRWeb - Mon Apr 14, 2:58AM CDT
Cosmetic as well as chemical companies are trying to market and sell their products by campaigning animal-free testing. Popular brands of cosmetics are implementing animal-free testing policies to market and sell their products. Vendors are targeting compassionate consumers by marketing their products as Cruelty-free food Cosmetics And clothing as cruelty-free testing does not damage the environment or produce harmful waste. Analysts forecast the Global In Vitro Toxicity Testing market will grow at a CAGR of 15.84 percent over the period 2013-2018. According to the report, the Global In Vitro Toxicity Testing market is driven by several factors, of which an increase in opposition to animal testing is one of the major drivers. Since animals are used as test subjects, toxicity testing is opposed by the majority of animal rights activists. This results in the increased adoption of in vitro toxicity testing and helps in the growth of the market. Covered in this Report The Global In Vitro Toxicity Testing market can be divided into four end-user segments: Cosmetics and Personal Care Industry, Pharmaceuticals Industry, Food Industry, and Chemicals Industry. The Global In Vitro Toxicity Testing Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the market. In addition, the report discusses the major drivers that influence the growth of the Global In Vitro Toxicity Testing market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. The report also includes a discussion of the key vendors operating in this market. Key Regions Americas EMEA APAC Key Vendors Accelrys Inc. Bio-Rad Laboratories Inc. Charles River Laboratories International Inc. Covance Inc. Purchase Report @ http://www.reportsnreports.com/purchase.aspx?name=280671. Other Prominent Vendors Entelos Inc. Mattek Corp. Molecular Toxicology Inc. RTI Health Solutions SBW Ltd. Smithers Group Inc. Xenobiotic Detection Systems Inc. Xenometrix AG Key Market Driver Increasing Opposition to Animal Testing. Key Market Challenge Concerns about Accuracy and Reliability of the Test. Key Market Trend Increase in Animal-free Testing Campaigns. Further, the report states that the accuracy and reliability of in vitro toxicity testing is one of the major challenges faced by the market vendors. In vitro toxicity testing requires proper laboratory setup as well as high-quality cell and tissue culture and good aseptic techniques. The report recognizes the following companies as the key players in Global In-vitro Toxicity Testing Market: Accelrys Inc., Bio-Rad Laboratories Inc., Charles River Laboratories International Inc. , Covance Inc. , Entelos Inc., MattekCorp., Molecular Toxicology Inc., RTI Health Solutions, SBW Ltd., Smithers Group Inc., Xenobiotic Detection SystemsInc., Xenometrix AG. Key Questions Answered in this Report What will the market size be in 2018 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?

Global In-Vitro Toxicology/Toxicity Testing (Cell Culture, HTS, Omics) Market 2014-2018
M2 - Wed Apr 09, 9:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59cs9d/invitro) has announced the addition of the "In-Vitro Toxicology/ Toxicity Testing Market by Industry, Technology, Applications & Method - Global Forecast to 2018" report to their offering. The global market of in-vitro toxicology testing is subdivided into industry, technology, method, application and geography. On the basis of industry, the market is further segmented into diagnostics, pharmaceuticals, chemicals, cosmetics, and food. Diagnostics is further categorized into sample and type. The largest market share was captured by the pharmaceutical industry, whereas cosmetics industry was the fastest growing industry with a double digit CAGR. The prime factor contributing to the growth of pharmaceutical industry has been the attention towards the detection of toxicity during earlier stages of development. On the basis of technology, the global market of in vitro toxicology testing is divided into cell culture, high throughput screening, cellular imaging, and omics technologies. Cell culture technology will witness the maximum growth rate in the coming years. The methods considered for the study are cellular assays, biochemical assays, ex vivo and in silico. Cellular assays market is estimated to grow at a double digit CAGR during the forecast period (2013-2018). Cellular assays can predict the biological properties of potential drug compounds. These assays can also detect and measure cell viability, functionality and growth. Under the applications, the market is segmented into systemic toxicity, dermal toxicity, ocular toxicity, endocrine disruption (reproductive & developmental toxicity) and others. Systemic toxicity testing was the largest segment in 2013. The increasing focus on detection of toxicity in earlier stages of development is leading to persistent requirement for human cell-based in vitro models for cardiotoxicity and liver toxicity testing which are the major reasons for drug attrition. Europe commanded the largest share of the global market in 2013. This is attributed to the support provided by the European government for anti-animal testing laws. The government has further put ban on the production and sale of all animal tested cosmetics across the continent. The market will be driven by increasing acceptance of in-vitro toxicology testing methods as alternatives to in vivo toxicology testing. The new technologies in the in vitro testing market help in investigating the adverse effects of environmental agents in a more mechanistic and time saving manner. Organizations such as REACH foresee that more results of in vitro and in silico methods will be included in risk assessment which will promote the use of in vitro methods for toxicology testing. Scope Industry - Diagnostic - Pharmaceutical - Cosmetics - Chemical Technology - Cell Culture - HTS - Omics Applications - Systemic - Dermal - Ocular Method - Cellular Assay - Ex vivo - In Silico Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - By Industry - By Technology - By Application - By Method - Geographic Analysis - Competitive Landscape - Company Profiles - Agilent Technologies, Inc. - Alere, Inc. - Bio-Rad Laboratories, Inc. - Bioreliance, Inc. - Catalent - Charles River Laboratories International, Inc. - Covance, Inc. - Cyprotex - Eurofins Scientific - GE Healthcare - Life Technologies Corporation - Quest Diagnostics Visit http://www.researchandmarkets.com/research/59cs9d/invitro

Charles River Laboratories Schedules First-Quarter 2014 Earnings Release and Conference Call
Business Wire - Mon Apr 07, 3:15PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2014 financial results on Wednesday, April 30th, after the market closes. A conference call has been scheduled to discuss this information on Thursday, May 1st, at 9:00 a.m. ET.

Pivotal Study Positive Results, Appointments, Proposed Public Offerings, Financial Results, and Product Launches - Analyst Notes on Amgen, Humana, Aetna, Perrigo, and Charles River
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Amgen Inc. (NASDAQ: AMGN),

Global Healthcare BPO Market 2013-2018 - Payer, Provider & Pharmaceutical Trends & Forecasts
M2 - Tue Apr 01, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnnrlm/healthcare_bpo) has announced the addition of the "Global Healthcare BPO Market 2013-2018 - Payer, Provider & Pharmaceutical Trends & Forecasts" report to their offering. The global healthcare BPO market is dominated by the U.S. A very large percentage of the healthcare BPO requirement arises out of the U.S. Europe is quickly emerging as another important source segment in this market. The U.S. and India are the two largest destination geographies. Philippines and Eastern Europe are two of the fastest growing destination segments in this market. The payer market is segmented into claims processing, member services, HR services, and finance and accounts segments. Claims processing is an important service segment in the payer outsourcing market. It is further sub-divided into claims indexing, claims investigation, claims adjudication, claims repricing, claims settlement, litigation management, and information management. The provider market is segmented into medical billing, medical coding, medical transcription, and finance and account segments. The pharmaceutical outsourcing market is segmented into contract research organizations (CRO), contract manufacturing organizations (CMO), and business support services. Each service segment in the pharmaceutical outsourcing market is divided into further sub-segments. The CRO service segment is sub-divided into drug discovery, pre-clinical, clinical phases I, II, III and IV, clinical data management and biostatistics, medical writing, regulatory services, and non-clinical functions. The CMO service segment is sub-divided into API manufacturing, and formulation and packaging. The non-clinical service segment is sub-divided into supply chain management and logistics, sales and marketing, and non-clinical functions. The report also highlights the marketing KPO function in the sales and marketing outsourcing segment. Scope Healthcare BPO Market Payer - Claims Processing - HR Services - Finance & Accounts Provider - Medical Billing & Coding Pharmaceutical - Clinical Trial - Contract Manufacturing - Non-Clinical Services Key Topics Covered: - Introduction - Executive Summary - Market Overview - Healthcare Payer Outsourcing Market - Healthcare Provider Outsourcing Market - Pharmaceutical Outsourcing Market - Geographical Analysis - Competitive Landscape - Company Profiles - Accenture Plc - Accretive Health, Inc. - Anthelio Healthcare Solutions, Inc. - Boehringer Ingelheim Gmbh - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. - Cognizant Technology Solutions Corporation - Covance, Inc. - Gebbs Healthcare Solutions, Inc. - Genpact Limited - Ibm Corporation - Icon Plc - Igate Patni - Infosys Bpo Limited - Inventiv Health Inc - Lonza Group Ltd. - Medusind Solutions Inc - Mphasis Limited - Omega Healthcare Management Services Pvt Ltd - Parexel International Corporation - Patheon Inc - Pharmaceutical Product Development, Inc. - Piramal Enterprises Limited - Quintiles Transnational Holdings, Inc. - Tata Consultancy Services Ltd - Tech Mahindra - Teleradiology Solutions Pvt Ltd. - Wns (Holdings) Limited - Xerox Corporation Visit http://www.researchandmarkets.com/research/hn...thcare_bpo

Charles River Laboratories and Galapagos complete transaction
GlobeNewswire - Tue Apr 01, 12:36AM CDT
Galapagos NV (Euronext: GLPG) confirms the completion of the transaction announced on 13 March 2014 to sell the BioFocus and Argenta service division operations to Charles River Laboratories International, Inc. (NYSE: CRL) for a total consideration of up to EUR134 million.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 60

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading

Top 5 Most Recently Viewed Articles

American Atomics Welcomes New Director and Operational Experts

Updated Category News Views 236

American Atomics Welcomes a New Addition to Its Leadership Team American Atomics Inc. (the "Company") is excited to announce the addition of Mr. Henrik Mikkelsen to its Board of Directors. With over 30 years of expertise in investment banking and energy trading, Mr. Mikkelsen will significantly bolster the company's direction. His recent role as Managing Partner and CIO...

Continue Reading
Coinbase Price Target Surges: Insights from Top Analysts

Updated Category News Views 127

Analyst Predictions for Coinbase's Future In the dynamic landscape of finance, the role of expert analysts becomes paramount, especially when it comes to predicting movements in stock prices. A recent surge in forecasts suggests that Coinbase Global, Inc. (NASDAQ: COIN) could experience substantial growth in its stock value. With the price target moving from $280 to an...

Continue Reading
Insights on Ultra Clean Holdings' Upcoming Class Action Lawsuit

Updated Category News Views 192

Understanding the Class Action Lawsuit Against Ultra Clean Holdings The Gross Law Firm is here to inform investors of Ultra Clean Holdings, Inc. (NASDAQ: UCTT) about an important class action lawsuit that is currently pending. This notice is directed towards shareholders who acquired shares of UCTT during the specified class period. The opportunity to participate in this...

Continue Reading
Logistics Automation Market Expected to Hit $85.19 Billion

Updated Category News Views 78

Growth of the Logistics Automation Market The logistics automation market is experiencing a transformative shift, with projections indicating that it will reach an impressive US$ 85.19 billion by 2030. This signifies a substantial increase from the US$ 35.21 billion recorded in 2022, with a compound annual growth rate (CAGR) of 11.7% expected over the period spanning 2022...

Continue Reading
Exploring Wynn Resorts' Recent Options Activity and Insights

Updated Category News Views 115

Understanding the Latest Trends in Wynn Resorts' Options Wynn Resorts has been capturing the attention of investors lately, particularly those who are willing to take a more aggressive approach in the marketplace. The underlying sentiment indicates strong, bullish activity surrounding Wynn Resorts (NASDAQ: WYNN). This is particularly significant for both institutional and...

Continue Reading